Mexico Insulin Drugs And Delivery Devices Market Trends

Statistics for the 2023 & 2024 Mexico Insulin Drugs And Delivery Devices market trends, created by Mordor Intelligence™ Industry Reports. Mexico Insulin Drugs And Delivery Devices trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of Mexico Insulin Drugs And Delivery Devices Industry

Rising diabetes prevalence

In Mexico, the diabetes population is expected to rise by about 3.4% over the forecast period.

According to IDF Diabetes Atlas 2021, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. An estimated 14 million adults in Mexico are living with diabetes. Additionally, 11 million adults in the country have impaired glucose tolerance, which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the highest total health expenditure. About 47.5% of people living with diabetes in the country are undiagnosed.

Lack of health insurance deprives the poor of access to services and puts them at risk of financial hardship. To protect the people against excessive health expenditures, Mexico has implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance. Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee's Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers for private-sector employees. The Seguro Popular (People's Insurance) was launched to protect the working-age population against steep healthcare costs. Enrolment in the Seguro Popular is independent of health status or pre-existing illness; there is no co-payment by the type of health care received, and family contributions are determined solely by the ability to pay.

Leading manufacturers focus on technological innovations and develop advanced insulin products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.

Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to grow over the analysis period.

Mexico Insulin Drugs and Delivery Devices Market, Type-1 Diabetes Population in million, 2017-2022

The insulin pumps segment is expected to witness the highest growth rate over the forecast period

An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.

Insulin Pump is expected to grow with a CAGR of about 9.9% in the market during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes people. Pumps are a validated, time-tested therapeutic option in type 1 diabetes at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.

The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients must check their blood glucose levels regularly, monitor their blood glucose levels, and adjust the insulin dosing accordingly, likely to drive segment growth during the forecast period. The use of continuous subcutaneous insulin infusion and continuous glucose monitoring systems has improved patient care and quality of life and is widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting.

The factors above are anticipated to drive market growth over the analysis period.

Mexico Insulin Drugs and Delivery Devices Market, Volume CAGR (%), by Insulin Delivery Devices, 2023-2028

Mexico Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)